Northwire Canada EditionMonday, July 27, 2026
Northwire
B 0.150 +0.0% IFOS 2.28 −2.6% IMM 0.060 +0.0% ROCK 3.38 −1.7% NVX 0.250 −7.4% HAR 0.050 +0.0% YGT 0.175 +0.0% GEN 0.070 −nan% CRB 0.040 +14.3% MSA 7.07 +2.2% AEM 204.81 +0.7% OPW 0.105 +5.0% GRL 0.275 −1.8% AIS 0.150 +0.0% CUU 0.580 −1.7% SOMA 0.720 +5.9% B 0.150 +0.0% IFOS 2.28 −2.6% IMM 0.060 +0.0% ROCK 3.38 −1.7% NVX 0.250 −7.4% HAR 0.050 +0.0% YGT 0.175 +0.0% GEN 0.070 −nan% CRB 0.040 +14.3% MSA 7.07 +2.2% AEM 204.81 +0.7% OPW 0.105 +5.0% GRL 0.275 −1.8% AIS 0.150 +0.0% CUU 0.580 −1.7% SOMA 0.720 +5.9%
Earnings

Kneat Announces Record Revenue for Third Quarter 2025

KSI · Price

Executive Summary

  • Kneat reported Q3 2025 revenue of C$16.1 M, up 26% YoY, and SaaS revenue of C$15.2 M, up 33% YoY.
  • Net loss narrowed to C$0.5 M from a net profit of C$1.2 M in Q3 2024; EBITDA fell to C$3.8 M but remains strong.
  • Annual Recurring Revenue (ARR) reached C$68.6 M, a 37% increase YoY, positioning the company for breakeven in 2026.

Key Details

  • Revenue & Growth
  • Total Q3 2025 revenue: C$16.1 M (+26% YoY).
  • SaaS revenue: C$15.2 M (+33% YoY, +8% QoQ).
  • Gross profit: C$12.2 M (+25% YoY).
  • Gross margin: 76% (down 1 pt from Q3 2024).

  • Profitability

  • Net loss Q3 2025: C$0.5 M vs. net income C$1.2 M in Q3 2024.
  • EBITDA Q3 2025: C$3.8 M (down from C$4.3 M YoY).
  • Adjusted EBITDA Q3 2025: C$2.5 M (down from C$2.9 M YoY).

  • Annual Recurring Revenue

  • ARR at Sep‑30 2025: C$68.6 M, up 37% YoY (from C$49.9 M).

  • Year‑to‑Date (YTD) Highlights (nine months)

  • Total revenue YTD: C$46.3 M (+31% YoY).
  • SaaS revenue YTD: C$43.2 M (+35% YoY).
  • Gross profit YTD: C$34.8 M (+32% YoY).
  • Net income YTD: C$1.3 M (vs. net loss of C$5.3 M in 2024).
  • EBITDA YTD: C$13.5 M (up from C$4.3 M).

  • Recent Business Wins

  • Signed three‑year Master Services Agreements with a global medical‑technology company, a global equipment manufacturer, and a leading multinational MedTech component maker (all announced Aug–Sep 2025).
  • Awarded top positions in three G2 Pharma & Biotech Fall 2025 Grid Report categories; overall G2 Satisfaction Score 98/100.

  • Product & AI Strategy

  • Ongoing AI enhancements aimed at faster content creation, review, and data‑driven decision making.

  • Conference Call

  • Management (CEO Eddie Ryan & CFO Dave O’Reilly) to discuss results on Thursday, Nov 13 2025 at 9:00 a.m. ET via webcast.

Notable Quotes

  • “This past quarter yielded more evidence of the durability of Kneat’s competitive advantage… we are upbeat about a solid finish to the year and our foundation for breakeven in 2026.” – Eddie Ryan, CEO
  • “New signings and existing customer expansions continue at strength. As we build upon our feature sets that will bring Kneat into new areas, the company’s financial future is exciting.” – Dave O’Reilly, CFO
Read the original news release →

More from KNEAT.COM, INC. J